spacer
home > ebr > winter 2002 > stem cells find a uk niche - the uk national stem cell initiative
PUBLICATIONS
European Biopharmaceutical Review

Stem Cells Find a UK Niche - The UK National Stem Cell Initiative

Until a few years ago, stem cells were the province of developmental biologists in academic laboratories. They now represent the hottest scientific and possibly commercial property of all the life sciences. Until recently, the clinical potential of stem cells was only in the narrow field of adult haematopoiesis. Now they are heralded as a treatment for a range of intractable diseases from cancer to Alzheimer's.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr John Sinden, Chief Scientific Officer of ReNeuron Holdings plc John Sinden was formerly Reader in Neurobiology of Behaviour at King's College London with a special expertise in neural transplantation. With two colleagues, he founded ReNeuron in 1997, joined the company as Chief Scientific Officer in 1998 and saw the company through a successful flotation on LSE AIM in late 2000.
He is Co-ordinator on the largest EC FP5-funded stem cell grant and occasionally advises the UK Government, its agencies and the EC on scientific, industrial and ethical issues in the stem cell field.

spacer
Dr John Sinden
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Running Better Trials Taking an Intelligent Monitoring Approach

Bioclinica

When it comes to implementing a risk-based monitoring program, it is not just about reducing monitoring visits and doing less Source Document Verification (SDV). Its about bringing together your people, a solid process, and the right technology to run a better trial. Success with risk-based monitoring requires the ability to make sense of the thousands, if not millions, of data points captured by multiple disparate sources in a clinical trial. With the sheer volume of data generated on a daily basis comes complexity. How does one make sense of it all? Information overload burdens even the most experienced study teams who struggle to understand which data matters most and what it means.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement